• Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Drug Extravasation Disposable Syringe Infusion Lead Cancer Chemotherapeutic Agent Oncological Society 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Brock N, Hilgard P, Peukert M, et al: Basis and new developments in the field of oxazaphosphorines. Cancer Invest 6: 513–532, 1988.PubMedCrossRefGoogle Scholar
  2. [2]
    Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.PubMedGoogle Scholar

Secondary literature

  1. [3]
    Asta Medica, personal communication, November 1998.Google Scholar
  2. [4]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  3. [5]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  4. [6]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 109–118, 1994.Google Scholar
  5. [7]
    Donislawski S, Gain M, Meyer-Jürshof A, et al: Cyclophosphamid: Behandlung von Paravasaten. In: Donislawski S, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 2: 39, 1994.Google Scholar
  6. [8]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  7. [9]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  8. [10]
    Dorr RT, Von Hoff DD: Drug monographs: cyclophosphamide. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 319–332, 1994.Google Scholar
  9. [11]
    Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.PubMedGoogle Scholar
  10. [12]
    Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations